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The role of putative DNA-binding domains of human papillomavirus (HPV) capsid proteins for DNA encapsidation in vivo
is still unknown. We have now analyzed mutants of the major capsid protein L1 of HPV type 33, which are defective for DNA
binding, for their ability to encapsidate DNA using an in vivo packaging approach. Since the DNA-binding domain and the
nuclear localization signal (NLS) of L1 overlap, both a carboxy-terminal deletion mutant (L1-1/470) and a substitution mutant
(L1-1/477M9) were analyzed. L1-1/477M9 has the classical NLS replaced by a noncanonical NLS taken from the human
hnRNP protein A1. The mutant proteins were defective for DNA binding in contrast to wild-type (wt) L1 proteins of several
HPV types. L1-1/470 localized to the cytoplasm when expressed in human cell lines, whereas L1-1/477M9 was found mainly
in the nucleus. When coexpressed with wt L2, mutant L1 proteins colocalized with L2 in nuclear domains 10 (ND10) similar
to wt L1 and assembled into virus-like particles incorporating L2. Wt L1 and L2 but not mutant L1 proteins and wt L2
efficiently encapsidated DNA and transferred it into cells, suggesting that physical interaction of L1 with DNA is essential for
DNA inclusion into VLPs. We also compared the infectivity of histone-free DNA-containing pseudovirions generated in vitro
with the infectivity of pseudovirions generated in vivo, which most likely harbor DNA in the form of chromatin. Pseudovirions
generated in vivo were, on a per genome basis, four to five times more infectious than pseudovirions generated in vitro, even
though no structural or biochemical difference was obvious. This indicates that chromatin may enhance the infectivity ofINTRODUCTION
Human papillomaviruses (HPVs) are widespread viruses
causing benign or malignant lesions of infected tissue.
They exclusively replicate in differentiating cells of the skin
and mucosa, mainly inducing warts (or papillomas) and
condylomata. Some lesions can progress to malignant in-
traepithelial lesions, e.g., invasive cervical carcinoma, the
second most frequent cancer of women worldwide. To
date, more than 100 types of HPV have been identified but
only a few are strongly associated with malignant transfor-
mations (zur-Hausen and de-Villiers, 1994).
Papillomaviruses contain a circular double-stranded
DNA genome of approximately 8000 bp in length that is
associated with histones to form a minichromosome
(Favre, 1975; Pfister et al., 1977). The icosahedral HPV
capsid of T  7 symmetry (Baker et al., 1991; Finch and
Klug, 1965) is composed of the major and minor capsid
proteins, L1 and L2. Capsids consist of 72 capsomeres,
each composed of 5 L1 molecules, and probably 12
copies of L2 protein (Sapp et al., 1995; Trus et al., 1997).
Intercapsomeric disulfide bonds between two highly
conserved cysteines covalently link L1 but not L2 protein
(Li et al., 1998; Sapp et al., 1998).
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172Since HPVs depend on terminally differentiating kera-
tinocytes for their replication, their propagation in cell
culture at large scale has been difficult. The synthesis of
L1 and L2 in heterologous expression systems has al-
lowed the high-yield production of virus-like particles
(VLPs) (Hagensee et al., 1993; Kirnbauer et al., 1992;
Rose et al., 1993; Volpers et al., 1994). These have been
shown to be a good vaccine candidate (Breitburd et al.,
1995; Suzich et al., 1995) and are amenable to genetic
analyses. Recently, several groups have succeeded in
encapsidation of marker DNA. Two principally different
approaches have been published. One relies on disso-
ciation and reassociation of partially purified VLPs in the
presence of histone-free plasmid DNA (Kawana et al.,
1998; Touze and Coursaget, 1998). The second approach
depends on the expression of capsid proteins in cells
carrying a marker plasmid at high copy number (Stauffer
et al., 1998; Unckell et al., 1997). In the latter case DNA
in the form of chromatin is most likely packaged in-
side papillomavirus capsids. Such in vivo generated
pseudovirions were recently used for the study of early
events in papillomavirus infection of cultured cells and
resulted in the identification of cell surface heparan sul-
fate as the candidate primary receptor for HPV (Giroglou
et al., 2001a).
Published reports on the requirements for DNA encap-pseudovirions. © 2002 Elsevier Science (USA)
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sidation are discordant. Whereas some groups found L2
to be indispensable for incorporation of DNA into papil-oning; DN
lomavirus capsids using various in vivo approaches for
generation of pseudovirions (Stauffer et al., 1998) and
pseudotyped virions (Roden et al., 1996), others ob-
served DNA encapsidation in the absence of L2 (Unckell
et al., 1997). L2 protein was not required for generation of
pseudovirions in vitro (Kawana et al., 1998, 2001; Touze
and Coursaget, 1998). Rather a DNA-binding domain,
which was mapped to the carboxy-terminus of L1, was
shown to be required for incorporation of histone-free
DNA into papillomavirus capsids (Touze et al., 2000). The
role of L2 protein in the context of mutant L1 has not
been studied. In addition, there are conflicting reports on
the identification of DNA-binding activities for L1 and/or
L2 (Li et al., 1997; Zhou et al., 1994). Taking advantage of
mutant L1 proteins, we have therefore undertaken to
analyze the role of the L1 DNA-binding domain in DNA
encapsidation in vivo. Here, we demonstrate that the
DNA-binding domain of L1 protein is essential for DNA
encapsidation in vivo. Furthermore, we found that
pseudovirions assembled in vivo are up to fivefold more
infectious than pseudovirions generated in vitro.
RESULTS
L1 but not L2 displays DNA-binding activity in
Southwestern blot analysis
To study the role of the DNA-binding domain of L1 in
DNA encapsidation in vivo, we constructed a series of L1
deletion mutants and expressed them in insect and in
mammalian cells using the baculovirus and vaccinia
virus expression systems, respectively. We first analyzed
their DNA-binding activity. To this end, mutant VLPs were
partially purified from insect cells and L1 proteins were
tested by Southwestern blot analysis (Fig. 1). It was
confirmed by Western blot analysis that similar amounts
of protein were loaded onto the gel (Fig. 1A). As shown
in Fig. 1B, wild-type (wt) L1 protein of HPV-16, -18, and -33
and an amino-terminal deletion mutant protein of HPV-33
(L1-21/499) bound DNA. Removal of the 7 carboxy-termi-
nal amino acids of HPV-33 L1 (L1-1/492) completely abol-
ished DNA-binding activity, as did deletion of 22 amino
acids (L1-1/477). HPV-33 L2 protein subjected to the
same analysis did not bind DNA under these conditions.
DNA binding observed in the L2 lane (below the 67-kDa
marker) did not coincide with the main proteins stained
in Western blot (between the 67- and the 94-kDa mark-
ers) and was probably due to cellular proteins in the
preparations. The carboxy-terminal 7-amino-acid peptide
of L1 was not sufficient for DNA binding, since dimeric
green fluorescent protein, to which this peptide has been
fused at the carboxy-terminus, did not display DNA-
binding activity (2GFP-NLS). The DNA binding of L1 was
completely abolished by preincubation of the blot with
peptide antiserum K890 directed against the carboxy-
terminal 15 amino acids of L1 (Fig. 1C). These data
indicate that the carboxy-terminal 7 amino acids of L1
are essential but not sufficient for DNA binding in this
heterologous environment. The same analysis with L1
proteins synthesized in COS-7 cells using recombinant
vaccinia viruses confirmed that a carboxy-terminal dele-
tion or substitution abolished DNA binding as shown in
Figs. 1D and 1E for wt 33L1, L1-1/470, and -1/477M9,
FIG. 1. Identification of the DNA-binding domain of HPV capsid proteins by Southwestern blot analysis. (A and D) Western blot analysis of input
proteins. (B, C, and E) Southwestern blot analysis. Wt capsid proteins of HPV-16, -18, and -33 as well as amino- and carboxy-terminally truncated or
substituted L1 mutant proteins of HPV-33 were synthesized by baculovirus expression (A, B, and C) and vaccinia virus expression (33wtL1, 1/470, and
1/477M9 in D and E). Proteins were purified by cesium chloride density gradient centrifugation and immunoprecipitation (2GFP-NLS), respectively,
subjected to SDS–PAGE, and transferred to nitrocellulose membranes. Membranes were blocked and incubated with radioactively labeled DNA. One
blot was incubated with K890 (diluted 1:100 in PBS) overnight at 4°C before the addition of DNA (C). Bound DNA was detected by autoradiography
(B, C, and E). The membranes were subsequently stained with a mixture of L1-, L2-, and GFP-specific antibodies (A and D) and corresponding
horseradish peroxidase-conjugated secondary antibodies. The molecular weights of marker proteins are indicated in kilodaltons.
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respectively. Copurifying cellular proteins were respon-
sible for the observed DNA binding in the L1-1/470 lane.
Fusion of a noncanonical nuclear localization signal
to nuclear transport-deficient L1 or coexpression with
wt L2 rescues nuclear import
The DNA-binding domain of L1 overlaps with its nu-
clear localization signal (NLS), which comprises the last
seven amino acids (Zhou et al., 1991). The carboxy-
terminal deletion mutants generated had therefore lost
their ability to undergo nuclear transport (Fig. 2A). Since
virions assemble in the nucleus of L1- and L2-expressing
cells and therefore require nuclear localization of L1, we
substituted the carboxy-terminal basic stretch of amino
acids for a noncanonical nuclear localization signal of 38
amino acids in length, which was derived from the hu-
man hnRNP A1 protein. The mutant protein L1-1/477M9
assembled to VLPs (data not shown) but displayed no
DNA-binding activity as measured by Southwestern blot
analysis (Figs. 1D and 1E). It was translocated into the
nucleus but not as efficiently as wt L1 (Fig. 2A). It also
accumulated in nuclear substructures, so-called nuclear
domains (ND) 10, in the presence of L2. ND10 have been
proposed as the location of papillomavirus assembly
(Day et al., 1998). Interestingly, coexpression of wt L2 and
nuclear transport-deficient L1-1/470 resulted in nuclear
translocation of the mutant L1 protein (Fig. 2A). In this
case, we even observed accumulation in ND10. This
suggests that the L2 protein is able to rescue nuclear
transport-deficient L1 protein. Upon coexpression with
L2, L1-1/470 and -1/477M9 incorporated the minor cap-
sid protein into VLPs as demonstrated by cosedimenta-
tion analysis (Fig. 2B and C).
The DNA-binding domain of L1 is essential for DNA
encapsidation in vivo
We next analyzed mutant L1 proteins for their ability to
encapsidate marker plasmid DNA using the in vivo pack-
aging approach (Unckell et al., 1997). Transfected COS
cells were infected with recombinant vaccinia viruses for
coexpression of mutant L1 and wt L2. COS cells infected
with vac33L1 and vac33L2 encoding wt L1 and L2, re-
spectively, served as controls, VLPs and pseudovirions
were extracted from nuclei and partially purified. Figure 3
shows the analysis of L1 protein across buoyant cesium
chloride density gradients. Wt L1 protein was found to
band in two broad peaks at densities of 1.29 and 1.32
g/cm3, respectively, when measured by L1-specific en-
zyme-linked immunosorbent assay (ELISA) (Fig. 3A). We
next isolated DNase I-resistant marker plasmid from
fractions across the gradient. Extensive dialysis for 6 h
prior to DNase I treatment was imperative for efficient
removal of unpackaged DNA molecules since DNase I
was inhibited by cesium ions. The number of colonies
growing in the presence of kanamycin after transforma-
tion of Escherichia coli served as a direct measure of the
amount of DNase I-resistant, i.e., encapsidated, DNA
molecules. Most fractions yielded a basic background of
FIG. 2. (A) Cellular localization of wt and mutant L1 proteins. Wt L1, L1-1/470, and L1-1/477M9 were expressed in HuTk cells alone or together
with HPV-33 wt L2 using recombinant vaccinia viruses. Localization of L1 was visualized by immunofluorescence using an L1-specific antibody. (B,
C) L2 incorporation into VLPs composed of L1-1/470 (B) and L1-1/477M9 (C). VLPs purified by buoyant cesium chloride gradient centrifugation were
subjected to sucrose step gradient analysis and fractions were analyzed by Western blot for the presence of L1 and L2. The molecular weights of
marker proteins are indicated in kilodaltons.
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20 to 40 colonies. Fractions yielding kanamycin-resistant
colonies significantly above background centered at a
density of 1.32 g/cm3, where pseudovirions are expected
to band (Fig. 3A). DNA analysis of randomly selected
clones obtained from these fractions revealed that they
almost exclusively contained the input marker plasmid
(Fig. 4), indicating that these molecules were inaccessi-
ble to DNase I. Aliquots of the same fractions were also
subjected to pseudoinfection assays. Infected cells were
observed only when fractions containing DNA signifi-
FIG. 3. DNA encapsidation into wt and mutant VLPs. L1 and L2 proteins of HPV-33 were expressed in marker plasmid-transfected COS-7 cells using
recombinant vaccinia viruses. VLPs and pseudovirions were extracted from nuclei and separated by cesium chloride density gradient centrifugation.
Gradients were fractionated, and the distribution of L1 was determined by L1-specific ELISA (A: wt L1 and wt L2; B: L1-1/470 and wt L2; C: L1-1/477M9
and wt L2). Fractions were additionally analyzed for infectivity (hatched bars) and DNase I-resistant DNA content (black bars). Fractions with the
largest numbers of infections were set as 100%. DNA content of fractions was measured by phenol extraction of DNA from DNase I-treated aliquots.
Isolated DNA was used to transform E. coli cells and the colonies growing in the presence of kanamycin were counted. Fractions with densities of
1.32 and 1.29 g/cm3 are indicated.
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cantly above background were added to COS cells (Fig.
3A). Infection was inhibited by preincubation of pseudo-
virions with homotypic VLP antiserum, confirming that
the DNA transfer is indeed capsid-mediated (data not
shown). Although different methods were used for quan-
tification of encapsidated plasmid, the calculated pack-
aging efficiency of marker plasmid into wt VLPs was
similar to that described by Unckell et al. (1997). When
mutant L1 (L1-1/470 and L1-1/477M9) was coexpressed
with wt L2 and nuclear extracts were subjected to den-
sity gradient centrifugation, the L1 banding pattern was
less pronounced, and only the L1 peak at 1.29 g/cm3 was
clearly visible (Figs. 3B and 3C). Analysis of DNase
I-resistant DNA exclusively yielded background levels of
kanamycin-resistant colonies. Plasmid DNA analysis of
individual clones revealed that most DNA molecules had
undergone significant rearrangement and deletions (Fig.
4). This indicates that the DNA was partially sensitive to
DNase I. Fractions with a density of approximately 1.32
g/cm3 did not contain infectious pseudovirions, no matter
if a carboxy-terminal L1 deletion or substitution mutant
protein was analyzed.
To exclude the possibility that loss of infectivity was
due to impaired binding of pseudovirions to cells, we
performed cell-binding assays. COS cells were incu-
bated with VLPs generated using the vaccinia virus ex-
pression system and bound L1 protein was detected by
Western blot. As shown in Fig. 5, wt and mutant VLPs
bound to COS cells, even though L1-1/470 bound some-
what more weakly than wt and L1-1/477M9. This is in line
with our recent observations that the carboxy-terminus of
L1 is not required for binding to heparan sulfate, the
proposed attachment receptor for HPV (Giroglou et al.,
2001a). Our data clearly demonstrate that the DNA-bind-
ing activity of L1 is essential for DNA encapsidation in
vivo and that L2 is not able to rescue this function, even
though L2-mediated nuclear translocation and accumu-
lation of mutant L1 in ND10 can be observed.
In vivo generated pseudovirions are more infectious
than pseudovirions assembled in vitro
We were intrigued as to whether the infectivity of
pseudovirions generated in vivo and in vitro differed.
Pseudovirions generated in vivo most likely harbor DNA
in the form of chromatin, since (i) it has been shown that
microinjection of naked DNA results in chromatinization
of the DNA within hours (Collingwood et al., 2001) and (ii)
the transfected plasmid is replicated in COS cells to high
copy numbers prior to encapsidation. DNA replication
and chromatin assembly in eukaryotic cells are coupled
processes (Sogo et al., 1986). In contrast, pseudovirions
generated in vitro after disassembly and reassociation of
purified VLPs in the presence of marker plasmid DNA
contain histone-free naked DNA (Kawana et al., 1998).
We therefore determined the number of encapsidated
DNA molecules in pseudovirions obtained with either
method. These data were then related to the number of
infectious units in the preparation. As shown in Fig. 6,
disassembly and reassociation of VLPs in the presence
of marker DNA yielded infectious pseudovirions that
banded at approximately 1.32 g/cm3 in cesium chloride
density gradients. The analysis of pseudovirions gener-
ated in vivo is shown in Fig. 3A. L2 protein was present
in both types of pseudovirions at comparable levels (data
not shown). Quantification of the encapsidated DNA mol-
ecules revealed that four- to fivefold more DNA mole-
cules were needed in the case of pseudovirions harbor-
ing naked DNA to obtain the same number of infection
events (Table 1). These data suggest that pseudovirions
assembled in vivo are up to fivefold more infectious than
pseudovirions generated in vitro.
Encapsidation of histone-free DNA induces
conformational changes in the papillomavirus capsid
We have recently shown that DNA encapsidation in
vivo induces a conformational change in the papilloma-
virus capsid resulting in complete disulfide bonding of
the L1 protein and a higher resistance to proteases
(Fligge et al., 2001). To address the possibility that the
FIG. 5. Cell-binding assay using HPV-33 mutant and wt VLPs. 30 ng
(lanes 2, 6, and 10), 60 ng (lanes 3, 7, and 11), or 120 ng (lanes 4, 8, and
12) of indicated VLPs was incubated with COS-7 cells. Cells were
washed and detached, and lysates were subjected to SDS–PAGE and
Western blot analysis using L1-specific antibody. 120 ng VLPs directly
subjected to SDS–PAGE served as controls (lanes 1, 5, and 9). The
molecular weights of marker proteins are indicated in kilodaltons.
FIG. 4. Analysis of DNase I-resistant DNA isolated from mutant and
wt pseudovirions. Randomly picked colonies obtained after transfor-
mation of E. coli cells with DNA extracted from cesium chloride gradi-
ent fractions with a density of 1.32 g/cm3 were amplified. DNA was
isolated, digested with restriction enzymes EcoRI and BamHI, and
analyzed by gel electrophoresis. The input plasmid served as control
(co). Numbers on the right show positions of DNA standards in kilo-
bases.
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differences in infectivity were due to differences in the
structure of these two kinds of pseudovirions, we ana-
lyzed the degree of disulfide cross-linking and the trypsin
sensitivity of pseudovirions generated in vitro. Figure 7A
shows that L1 protein, assembled to pseudovirions in
vitro, was almost completely disulfide bonded, suggest-
ing that encapsidation of histone-free DNA induces a
conformational change in the papillomavirus capsid
also. VLPs of the same gradient, banding at a density of
1.29 g/cm3, displayed 50% disulfide cross-linking in
agreement with previous observations (Fligge et al.,
2001; Sapp et al., 1998). The DNA-induced structural
change is confirmed by our observation that pseudoviri-
ons generated in vitro are also partially resistant to
trypsin digestion (Fig. 7B). Infectivity of pseudovirions
even increased after treatment with trypsin for 2 h. Sim-
ilar observations have been made for pseudovirions gen-
erated in COS cells (Fligge et al., 2001).
We conclude that pseudovirions generated in vivo and
in vitro have similar structural properties and that the
increased infectivity of pseudovirions generated in COS
cells is therefore due to the presence of chromatin.
DISCUSSION
We have reported here that the L1 protein of HPV-16,
HPV-18, and -33 but not HPV-33 L2 displays DNA-binding
activity in Southwestern blot analysis. The DNA-binding
activity is confined to the very carboxy-terminus of L1. We
have also shown that the DNA-binding domain was es-
sential for encapsidation of marker plasmid DNA in an in
vivo DNA packaging approach. L2 protein, even though
present during virus morphogenesis and incorporated
into the capsids, did not rescue DNA encapsidation of
mutant capsids. This is in agreement with our observa-
tion that DNA encapsidation in vivo does not require L2
protein in this system (Unckell et al., 1997). For the first
time we have demonstrated that, on a per genome basis,
in vivo assembled pseudovirions are more infectious
than in vitro assembled pseudovirions.
Published results concerning the DNA-binding activity
of the major and minor capsid proteins L1 and L2 are
discordant. Whereas Zhou et al. (1994) observed a DNA-
binding activity of HPV-16 L2 but not of L1 in Southwest-
ern blot analysis, Li et al. (1997) and Touze et al. (2000)
mapped DNA-binding activity to the very carboxy-termi-
nus of HPV-11 and HPV-16 L1, respectively. A weak DNA-
binding activity of the amino-terminal 12 amino acids of
HPV-16 L2 was also observed when fused to the VP60
capsid protein of the rabbit hemorrhagic disease virus
(El Mehdaoui et al., 2000). One likely explanation for the
discordant results may be slight differences in the blot
renaturation and/or salt concentrations in the wash buff-
ers, which could result in different sensitivities of the
assays applied. Our Southwestern blot analyses suggest
FIG. 6. DNA encapsidation in vitro using HPV-33 L1/L2-VLPs. L1/L2-VLPs were disassembled and reassembled in the presence of marker plasmid
DNA and subjected to cesium chloride density gradient centrifugation. The gradient was fractionated, and the distribution of L1 protein was
determined by L1-specific ELISA. Fractions were additionally analyzed for infectivity (hatched bars) and DNase I-resistant DNA content (black bars).
Fractions with the largest numbers of infections were set as 100%. Fractions with densities of 1.32 and 1.29 g/cm3 are indicated.
TABLE 1
Quantification of DNase I-Resistant Marker Plasmid
and Pseudoinfections
Experiment
No.
Colony
numbersa
Infected
cellsb Ratioc
In vivo
1 14,873 190 78
2 18,529 211 87
In vitro
1 6,810 20 340
2 8,884 23 386
a Colony numbers obtained after electroporation of E. coli with DNA
extracted from pseudovirions were corrected for transformation effi-
ciency.
b Infectivity was determined as described under Materials and Meth-
ods using eukaryotic COS-7 cells.
c Ratio of colony numbers and infected cells.
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that L1 protein binds to DNA, which is supported by the
necessity of the L1 domain for DNA encapsidation in
vivo. We cannot rule out the possibility that L2 has a
weak DNA-binding activity not detectable in our assay
system.
The L1 deletion mutants analyzed in this study were
able to assemble efficiently into VLPs including incorpo-
ration of L2, suggesting that capsid assembly was not
impaired. This is in line with published reports showing
that short deletions and substitutions at the carboxy-
terminus of L1 of bovine, canine, and human papilloma-
viruses allow efficient VLP formation (Chen et al., 1998;
Mu¨ller et al., 1997; Paintsil et al., 1996). Interestingly, L2
protein was able to rescue nuclear transport-deficient L1
protein and even induced its accumulation in ND10.
ND10, also known as PML oncogenic domains, have
been proposed as a site of virus morphogenesis (Day et
al., 1998). The reason for the inability of L1 mutants to
package DNA can therefore not be attributed to changes
in their subnuclear localization. Our data strongly sug-
gest that the interaction between L1 and DNA mediates
DNA encapsidation and is essential for virion formation
in vivo. A recently published report proposed a role of the
DNA-binding domain of L1 for pseudovirion formation in
vitro (Touze et al., 2000). However, since this study was
done with purified components and did not address the
role of L2 and the cellular environment, it was not clear
whether these conclusions apply to virion formation in
the context of intact cells.
The role of the proposed DNA-binding activity of L2 in
virus morphogenesis remained obscure until now. Sev-
eral groups have shown that DNA encapsidation does
not require L2 protein, even though L2 enhances infec-
tivity of virions (Kawana et al., 1998, 2001; Unckell et al.,
1997). The systems used include reassociation of cap-
someres in the presence of marker plasmid and gener-
ation of pseudovirions in transfected COS cells. Others,
using different systems to obtain pseudotyped virions,
found L2 to be essential for efficient DNA encapsidation
(Roden et al., 1996; Stauffer et al., 1998; Zhao et al., 1998).
We now clearly demonstrate that the DNA-binding do-
main of L1 is essential for DNA encapsidation. As L2
protein cannot rescue mutant L1 for DNA encapsidation,
it alone is not sufficient for packaging of DNA into the
capsid. This is line with a recent report stating that the
proposed DNA-binding domain of L2 (Zhou et al., 1994) is
not involved in DNA encapsidation (Roden et al., 2001).
Taken together, these results suggest that L2 protein
rather serves functions different from directly interacting
with DNA during virus morphogenesis. It has recently
been shown that L2 attracts L1 into ND10 (Day et al.,
1998). Viral DNA replication seems to take place at ND10
(Swindle et al., 1999). We have observed that L2 reorga-
nizes these structures, possibly paving the way for viral
chromatin condensation prior to L1-mediated DNA en-
capsidation (Florin et al., 2002). L2 may therefore be
indirectly involved in DNA encapsidation, without inter-
acting with DNA itself. The different effects of L2 on DNA
encapsidation observed in different studies may be due
to differences in the systems used for generation of
pseudovirions.
Our data strongly indicate that pseudovirions gener-
ated in vivo are more infectious than pseudovirions gen-
erated in vitro, even though the structural properties
seem to be very similar. Since in vivo generated
pseudovirions are highly likely to contain DNA in the
form of chromatin, structural differences of the encapsi-
dated DNA rather than that of the capsid may account for
the increased infectivity. This could be due to a more
efficient nuclear translocation of the DNA once it is
released from endosomes into the cytoplasm. Alterna-
tively, chromatin may be more resistant to nucleases
than naked DNA and therefore may be more likely to
reach its nuclear destination. This may be important for
the design of papillomavirus capsids as gene transfer
vehicles. From already published data it is clear that L2
protein is important for efficient gene transfer into cul-
tured cells. Therefore, it should be included in a papillo-
mavirus-based gene transfer vector (Kawana et al., 1998;
Roden et al., 2001; Unckell et al., 1997). The use of DNA
FIG. 7. Disulfide cross-linking and trypsin sensitivity of HPV-33 pseudovirions generated in vitro. (A) Cross-linking analysis was performed using
VLPs and pseudovirions composed of HPV-33 L1 and L2. Capsid proteins were separated on a nonreducing gel, and L1 protein was detected by
L1-specific antibody after transfer to nitrocellulose membrane. (B) In vitro generated pseudovirions were incubated with trypsin for the indicated
periods of time exactly as described previously (Fligge et al., 2001). Trypsin digestion was stopped by addition of trypsin inhibitor and pseudovirions
were subsequently used to infect COS-7 cells. Infected cells were counted. The number of infections in the control (0 h) was set as 100%.
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in the form of chromatin instead of histone-free plasmid
DNA may add to the infectivity of papillomavirus-based
pseudovirions. It will be interesting to test the generation
and infectivity of chromatin-harboring pseudovirions us-
ing purified components.
MATERIALS AND METHODS
Cell lines, recombinant vaccinia viruses, and
baculoviruses
Sf9 insect cells were grown in supplemented Grace’s
insect medium (Gibco) containing 10% FCS at 27°C.
Human cell lines (293, HuTk) were grown in DMEM
supplemented with 10% FCS at 37°C. The generation
of recombinant vaccinia viruses vac33L1 and vac33L2
(Unckell et al., 1997) and recombinant baculoviruses
bac33L1 and bac33L2 (Volpers et al., 1994) has been
described previously. The recombinant vaccinia virus
VTF7-3 was kindly provided by Bernhard Moss.
Southwestern blot
Southwestern blot analyses were performed following
the protocol published by Li et al. (1997).
Mutagenesis and generation of recombinant
baculoviruses and vaccinia viruses
To generate the baculovirus transfer vector pVL33L1-
1/477M9, the amino-terminal 477 codons of HPV-33 L1
were amplified by polymerase chain reaction (PCR)
from pVL1 (Volpers et al., 1994) using 5-TTAGAATTCAT-
GTCCGTGTGGCGGCCT-3 (33L1-1-5) as forward primer
and 5-ACCGGATCCAGGTTTTGCTTTAAG-3 as reverse
primer. An EcoRI and a BamHI recognition site (boldface
type) had been added. The PCR fragment was digested
with EcoRI and BamHI and cloned into the respective
sites of pVL1392, resulting in pVL33L1-1/477. The M9
sequence was obtained by RT-PCR using the forward
primer 5-GAATGGATCCAATCAGTCTTC-3 and reverse
primer 5-GCTGGATCCTTAATAGCCACC-3, and total
RNA, extracted from 293 cells using an RNA extraction
kit (Qiagen), as template. The fragment was digested
and cloned into the BamHI site of pVL33L1-1/477 to
obtain pVL33L1-1/477M9. The vaccinia virus transfer
vector pTM33L1-1/477M9 was generated by amplifica-
tion of the HPV-33 L1 open reading frame from pVL33L1-/
477M9 using the forward primer 33L1-1-5 and reverse
primer 5-CAGGAAAAGATCTTTAATAGCC-3. The frag-
ment was digested with EcoRI and BglII and cloned into
the EcoRI and BamHI site of pTM1. Carboxy-terminal
deletion mutants of L1 of HPV-33 were obtained by PCR
using pVL1 as template and oligonucleotide 33L1-1-5 as
forward primer. The following oligonucleotides were
used as reverse primer: 5-CCTGAATTCTTATGCAGAC-
GATGTGCGGGT-3 (33L1-492S-3), 5-ACCGAATTCTTA-
AGGTTTTGCTTTAAGACC-3 (33L1-477S-3), and 5-CGG-
GAATTCTTATGGGTTACCATTTTCATCAAATGGCTGTAAT-
AAAAACTT-3 (33L1-470-3). The amino-terminal deletion
mutant 33L1-21/499 was generated by PCR using oligo-
nucleotides 5-GCCGAATTCATGGTTGTCAGCACTGAT-
GAA-3 and 5-CCGGAATTCAAGTACATAGACAGAACA-
3. Upstream of the ATG and downstream of the stop
codon, recognition sites for EcoRI had been added. L1-
1/470-3 has an 8-amino-acid epitope tag fused to its
carboxy-terminus. The PCR products were separated by
agarose gel electrophoresis, eluted from the gel, cut with
EcoRI, and ligated to pVL1392 (1/492, 1/477, and 21/499)
and pTM1 (1/470), which had been cut correspondingly.
The vector–L1 junctions of all plasmids were verified by
sequencing. The baculovirus transfer vectors obtained,
pVL-33L1-1/492, -1/477, -1/477M9, and -21/499, were co-
transfected into Sf9 insect cells by calcium phosphate
precipitation together with BaculoGold DNA (Pharmin-
gen), following the vendor’s protocol to obtain recom-
binant baculoviruses bac33L1-1/492, -1/477, -1/477M9,
and -21/499, respectively. The vaccinia virus transfer vec-
tors pTM33L1-1/470 and pTM33L1-1/477M9 were co-
transfected by calcium phosphate precipitation together
with wildtype vaccinia virus DNA, and recombinant vi-
ruses were selected and plaque-purified as described
(Moss et al., 1990; Unckell et al., 1997).
Plasmid extraction from pseudovirions and
electroporation of E. coli
Plasmid extraction was carried out following the pro-
tocol of Zhao et al. (1998) with some modifications. In
brief, 100 l of cesium chloride density gradient fractions
was dialyzed against H2O for 6 h with three changes of
dialysis buffer in a microdialysis machine using microdi-
alysis tubes. Following dialysis, 10 mM MgCl2 and 250
g/ml DNase I were added to the samples and incu-
bated for 1 h at 37°C. Following phenol/chloroform ex-
traction, DNA was ethanol precipitated overnight at
20°C and subsequently resolved in 15 l H2O. For
transformation 20 l of ELECTROMAX DH5-E cells (Life
Technologies) was mixed on ice with 3 l of the DNA
sample and transferred into a microelectroporation
chamber. Electroporation was done according to the
manufacturer’s suggestions using a Gibco BRL CELL-
PORATOR and Voltage Booster. pUC19 DNA served as a
control to determine the transformation efficiency. Trans-
formed E. coli were spread onto LB plates containing
kanamycin and incubated at 37°C for 20 h.
Analysis of encapsidated plasmid DNA
After transformation of E. coli with DNA extracted from
pseudovirions, antibiotic-resistant colonies were ran-
domly picked and amplified. DNA was prepared using a
commercially available DNA extraction kit (Peqlab, Erlan-
gen, Germany), digested with restriction enzymes EcoRI
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and BamHI, and subjected to a 1% agarose gel electro-
phoresis.
Preparation of pseudovirions
Pseudovirions were generated in vivo as described
previously (Giroglou et al., 2001b; Unckell et al., 1997).
Pseudovirions were generated in vitro exactly as de-
scribed by Kawana et al. (1998) using pGFPGFP-NLS as
marker plasmid.
Infection assay
For pseudoinfection, 100 l of pseudovirions dialyzed
overnight was treated with DNase I (250 g/ml) for 1 h at
37°C and subsequently incubated with COS cells that
had been seeded 18 h prior to infection into 24-well
plates (5  104 cells/well). Infection was carried out in a
total volume of 250 l PBS–100 g/ml BSA, pH 6.8. After
1 h at 4°C the pseudovirions were replaced by 1 ml
supplemented culture medium. Cells were grown for
72 h at 37°C. The number of infections was determined
by counting fluorescent cells.
Enzyme-linked immunosorbent assay
Two microliters of each fraction of the cesium chloride
density gradient was denatured in carbonate buffer, pH
9.6, and coupled overnight at RT to microtiter plates. After
washing and blocking of the plates L1 was visualized
with monoclonal antibody 33L1-7 and horseradish per-
oxidase-coupled secondary antibody using tetramethyl-
benzidine as substrate.
Preparation of VLPs
VLPs were generated in insect cells as previously
published by Volpers et al. (1994).
Immunofluorescence
HuTK cells were grown on coverslips overnight. They
were subsequently infected with the indicated recombi-
nant vaccinia viruses for 1 h at RT. After incubation for an
additional 12 h at 37°C cells were fixed in methanol
containing 0.02 M EGTA at 20°C for 30 min, washed
twice in PBS, and blocked in PBS containing goat serum
for 1 h at 37°C. They were subsequently incubated for
1 h at 37°C with L1- (33L1-7) and L2-specific (K28)
monoclonal and polyclonal antibodies, respectively.
Bound antibodies were detected with Cy3-conjugated
Affinipure goat anti-rabbit IgG and DTAF-conjugated Af-
finipure goat anti-mouse IgG for 1 h at 37°C. Coverslips
were washed several times with PBS and mounted on
slides with Vectashield mounting medium. Fluorescence
was examined using a Leica DM RBE fluorescence mi-
croscope and a KOHU digital camera.
Cell-binding assay
COS cells were seeded into 24-well plates and grown
to confluency. Adherent cells were washed four times
with PBS, pH 6.8, and incubated for 90 min on ice with
the indicated VLPs dissolved in 200 l PBS, pH 6.8,
containing 100 g/ml BSA under constant agitation. Cells
were washed four times with PBS, pH 6.8, detached in 40
l sample buffer (Laemmli, 1970), and boiled for 5 min.
Proteins were analyzed by SDS–PAGE followed by West-
ern blot with L1-specific antibody 33L1-7 and horserad-
ish peroxidase-coupled secondary antibody. The signal
was visualized by enhanced chemiluminescence (Amer-
sham).
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